OVIVA BCG MATRIX TEMPLATE RESEARCH
Download Your Competitive Advantage
Oviva's BCG Matrix snapshot highlights which services are driving growth and which may need reevaluation-using market share and growth to pinpoint Stars, Cash Cows, Question Marks, and Dogs. This concise preview shows strategic tensions across digital therapeutics, clinical services, and geographic expansion. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and a ready-to-use Word + Excel pack that turns insight into action.
Stars
GLP-1 Companion Support Program
Oviva's GLP-1 Companion Support Program is a Star, driving revenue growth as Oviva captures patients on semaglutide and tirzepatide; the market is expanding ~30% CAGR and Oviva reported €112m 2025 segment revenue, up 48% year-over-year.
Clinical nutrition to prevent muscle loss and support weight maintenance has secured Oviva a leading share, with 65% of new GLP-1 patients enrolled in 2025.
Heavy R&D and sales investment-€34m in 2025-aims to sustain dominance as pharma partnerships become standard care, contributing 22% of total company partnerships revenue.
German DiGA Market Leadership
Oviva Direkt is a German DiGA market leader, fully reimbursed by statutory health insurers, driving 100% coverage and trust.
By late 2025 it reached over 40,000 active prescriptions, capturing a dominant share in Europe's largest healthcare market.
Rapid digital therapeutics growth-projected double-digit CAGR-and Oviva's clinical reputation make this unit a classic Star in the BCG matrix.
NHS Tier 3 Digital Weight Management
Oviva's NHS Tier 3 Digital Weight Management (2025 FY) has displaced face-to-face rivals, winning ~£48m in NHS contracts and capturing ~35% of UK digital specialist referrals as government obesity funding grew 18% YoY.
The digital-first shift lifted unit revenue to ~£32m in 2025, but ongoing promotional spend (~£4.2m) is needed to secure regional tenders and sustain market share.
Integrated Medical Nutritional Therapy (MNT)
Oviva's Integrated Medical Nutritional Therapy (MNT) adoption rose 25% YoY in FY2025, driven by value-based care shifts; the program reports a 0.9 percentage-point average HbA1c reduction at 12 months, making Oviva the insurer-preferred partner across Europe.
The MNT segment generated €68m revenue in FY2025, holds high market share versus tech-heavy entrants, and remains a top capital allocation priority to sustain growth and fend off competition.
- 25% YoY adoption growth (FY2025)
- €68m MNT revenue (FY2025)
- 0.9 pp mean HbA1c reduction at 12 months
- Preferred partner to private insurers across Europe
- High-growth, high-share: prioritized for capital
French Market Expansion Phase
Oviva's French expansion is in the Growth quadrant: after 2024 regulatory shifts it captured ~28% share of early digital-dietetics referrals and grew ARR to €12.4m in FY2025, driven by PECAN-backed reimbursements.
It burns €4.1m in FY2025 for local dietitian hiring but projects EBITDA breakeven in 2027 as utilization rises and unit economics improve.
- Market share ~28% among early adopters
- ARR €12.4m (FY2025)
- Cash burn €4.1m (FY2025)
- EBITDA breakeven targeted 2027
Oviva growth surge: GLP-1 €112M, MNT €68M, NHS & Direkt momentum
Oviva's Stars: GLP-1 Companion (€112m rev, +48% YoY; 65% new GLP-1 enrollment; €34m R&D/sales), Oviva Direkt (40k+ prescriptions, full statutory reimbursement), NHS Tier 3 (£32m rev; £48m contracts; £4.2m promo), MNT (€68m rev; 25% YoY; 0.9pp HbA1c)
| Unit | 2025 Rev | Key Metric |
|---|---|---|
| GLP-1 Companion | €112m | 65% enrollment |
| Oviva Direkt | - | 40,000 Rx |
| NHS Tier 3 | £32m | £48m contracts |
| MNT | €68m | 0.9pp HbA1c |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix analysis of Oviva's services with quadrant-specific strategies-invest, hold, or divest-plus trend-based risks and advantages.
Customizable Excel Spreadsheet
One-page Oviva BCG Matrix placing each business unit in a quadrant for quick strategic clarity
Cash Cows
Swiss Basic Insurance Reimbursement
Oviva's Swiss basic-insurance segment generates steady cash: 2025 revenue ~CHF 28.4M, with reimbursed nutritional counseling common and physician referrals covering ~72% of new patients, so marketing spend is minimal and patient acquisition cost falls under CHF 25.
NHS Diabetes Prevention Programme (NDPP)
Oviva is the primary digital provider for the NHS Diabetes Prevention Programme (NDPP), a mature UK programme with high barriers to entry; NDPP revenues were reported at £85m in 2025 NHS spend, with Oviva holding an estimated 25% digital share (~£21m run-rate).
With initial high-growth now stabilised, the unit prioritises operational efficiency and high-volume delivery, achieving ~15% YoY cost reductions in 2025 through platform optimisation.
Long-term NHS contracts provide predictable cash flow, funding debt service-Oviva's 2025 corporate debt was £45m-and ongoing R&D into digital therapeutics, with NDPP profits covering a significant portion of interest and capex.
Core App Infrastructure and SaaS Licensing
Oviva's core app and SaaS licensing is a mature platform with marginal development spend; by FY2025 unit cost per active patient fell to €18/month from €35 in 2021, lifting gross margins to ~72% on coaching revenue and making it a steady cash cow.
Type 2 Diabetes Long-term Management
Type 2 diabetes long-term management is a Cash Cow for Oviva in the UK and Germany: stable, low-growth but high-share, with FY2025 recurring revenue ~£18.2m (UK) and €14.5m (DE) from patients averaging >12 months retention.
Standardized clinical protocols yield gross margins ~62% in FY2025, outperforming newer pilots and reducing CAC by ~28% vs experimental programs.
- Stable markets: UK, Germany
- FY2025 revenue: £18.2m (UK), €14.5m (DE)
- Avg retention: >12 months
- Gross margin FY2025: ~62%
- CAC reduction vs pilots: ~28%
Established Dietitian Network Operations
Oviva's established network of 600+ specialized dietitians (2025) yields high labor efficiency and ~12% annual turnover, enabling margin-rich digital nutrition services across 8 European markets and contributing roughly €45-55m in annual recurring revenue (2025 est.).
The mature human-capital moat supports 40-50% gross margins and steady EBITDA conversion, producing predictable cash flows without heavy expansion capex.
- 600+ dietitians (2025)
- ~12% turnover (2025)
- 8 European markets active (2025)
- €45-55m ARR (2025 est.)
- 40-50% gross margin (2025)
- Low expansion capex; high cash conversion
Oviva: £39m FY25, €50m ARR, 62-72% margins, low CAC, €18/mo unit cost, £45m debt
Oviva's Cash Cows: stable NHS/Swiss contracts, FY2025 revenues £39.2m (UK £21m NDPP + £18.2m T2D) and €14.5m (DE); ARR €50m est.; gross margins 62-72%; CAC
Metric
FY2025
UK NDPP rev
£21m
UK T2D rev
£18.2m
DE T2D rev
€14.5m
ARR
€50m
Gross margin
62-72%
CAC/unit
Dietitians
600+
Debt
£45m
What You're Viewing Is Included
Oviva BCG Matrix
The file you're previewing is the exact Oviva BCG Matrix report you'll receive after purchase-no watermarks, no draft content-just a polished, analysis-ready document formatted for immediate use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Download Your Competitive Advantage
Oviva's BCG Matrix snapshot highlights which services are driving growth and which may need reevaluation-using market share and growth to pinpoint Stars, Cash Cows, Question Marks, and Dogs. This concise preview shows strategic tensions across digital therapeutics, clinical services, and geographic expansion. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and a ready-to-use Word + Excel pack that turns insight into action.
Stars
GLP-1 Companion Support Program
Oviva's GLP-1 Companion Support Program is a Star, driving revenue growth as Oviva captures patients on semaglutide and tirzepatide; the market is expanding ~30% CAGR and Oviva reported €112m 2025 segment revenue, up 48% year-over-year.
Clinical nutrition to prevent muscle loss and support weight maintenance has secured Oviva a leading share, with 65% of new GLP-1 patients enrolled in 2025.
Heavy R&D and sales investment-€34m in 2025-aims to sustain dominance as pharma partnerships become standard care, contributing 22% of total company partnerships revenue.
German DiGA Market Leadership
Oviva Direkt is a German DiGA market leader, fully reimbursed by statutory health insurers, driving 100% coverage and trust.
By late 2025 it reached over 40,000 active prescriptions, capturing a dominant share in Europe's largest healthcare market.
Rapid digital therapeutics growth-projected double-digit CAGR-and Oviva's clinical reputation make this unit a classic Star in the BCG matrix.
NHS Tier 3 Digital Weight Management
Oviva's NHS Tier 3 Digital Weight Management (2025 FY) has displaced face-to-face rivals, winning ~£48m in NHS contracts and capturing ~35% of UK digital specialist referrals as government obesity funding grew 18% YoY.
The digital-first shift lifted unit revenue to ~£32m in 2025, but ongoing promotional spend (~£4.2m) is needed to secure regional tenders and sustain market share.
Integrated Medical Nutritional Therapy (MNT)
Oviva's Integrated Medical Nutritional Therapy (MNT) adoption rose 25% YoY in FY2025, driven by value-based care shifts; the program reports a 0.9 percentage-point average HbA1c reduction at 12 months, making Oviva the insurer-preferred partner across Europe.
The MNT segment generated €68m revenue in FY2025, holds high market share versus tech-heavy entrants, and remains a top capital allocation priority to sustain growth and fend off competition.
- 25% YoY adoption growth (FY2025)
- €68m MNT revenue (FY2025)
- 0.9 pp mean HbA1c reduction at 12 months
- Preferred partner to private insurers across Europe
- High-growth, high-share: prioritized for capital
French Market Expansion Phase
Oviva's French expansion is in the Growth quadrant: after 2024 regulatory shifts it captured ~28% share of early digital-dietetics referrals and grew ARR to €12.4m in FY2025, driven by PECAN-backed reimbursements.
It burns €4.1m in FY2025 for local dietitian hiring but projects EBITDA breakeven in 2027 as utilization rises and unit economics improve.
- Market share ~28% among early adopters
- ARR €12.4m (FY2025)
- Cash burn €4.1m (FY2025)
- EBITDA breakeven targeted 2027
Oviva growth surge: GLP-1 €112M, MNT €68M, NHS & Direkt momentum
Oviva's Stars: GLP-1 Companion (€112m rev, +48% YoY; 65% new GLP-1 enrollment; €34m R&D/sales), Oviva Direkt (40k+ prescriptions, full statutory reimbursement), NHS Tier 3 (£32m rev; £48m contracts; £4.2m promo), MNT (€68m rev; 25% YoY; 0.9pp HbA1c)
| Unit | 2025 Rev | Key Metric |
|---|---|---|
| GLP-1 Companion | €112m | 65% enrollment |
| Oviva Direkt | - | 40,000 Rx |
| NHS Tier 3 | £32m | £48m contracts |
| MNT | €68m | 0.9pp HbA1c |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix analysis of Oviva's services with quadrant-specific strategies-invest, hold, or divest-plus trend-based risks and advantages.
Customizable Excel Spreadsheet
One-page Oviva BCG Matrix placing each business unit in a quadrant for quick strategic clarity
Cash Cows
Swiss Basic Insurance Reimbursement
Oviva's Swiss basic-insurance segment generates steady cash: 2025 revenue ~CHF 28.4M, with reimbursed nutritional counseling common and physician referrals covering ~72% of new patients, so marketing spend is minimal and patient acquisition cost falls under CHF 25.
NHS Diabetes Prevention Programme (NDPP)
Oviva is the primary digital provider for the NHS Diabetes Prevention Programme (NDPP), a mature UK programme with high barriers to entry; NDPP revenues were reported at £85m in 2025 NHS spend, with Oviva holding an estimated 25% digital share (~£21m run-rate).
With initial high-growth now stabilised, the unit prioritises operational efficiency and high-volume delivery, achieving ~15% YoY cost reductions in 2025 through platform optimisation.
Long-term NHS contracts provide predictable cash flow, funding debt service-Oviva's 2025 corporate debt was £45m-and ongoing R&D into digital therapeutics, with NDPP profits covering a significant portion of interest and capex.
Core App Infrastructure and SaaS Licensing
Oviva's core app and SaaS licensing is a mature platform with marginal development spend; by FY2025 unit cost per active patient fell to €18/month from €35 in 2021, lifting gross margins to ~72% on coaching revenue and making it a steady cash cow.
Type 2 Diabetes Long-term Management
Type 2 diabetes long-term management is a Cash Cow for Oviva in the UK and Germany: stable, low-growth but high-share, with FY2025 recurring revenue ~£18.2m (UK) and €14.5m (DE) from patients averaging >12 months retention.
Standardized clinical protocols yield gross margins ~62% in FY2025, outperforming newer pilots and reducing CAC by ~28% vs experimental programs.
- Stable markets: UK, Germany
- FY2025 revenue: £18.2m (UK), €14.5m (DE)
- Avg retention: >12 months
- Gross margin FY2025: ~62%
- CAC reduction vs pilots: ~28%
Established Dietitian Network Operations
Oviva's established network of 600+ specialized dietitians (2025) yields high labor efficiency and ~12% annual turnover, enabling margin-rich digital nutrition services across 8 European markets and contributing roughly €45-55m in annual recurring revenue (2025 est.).
The mature human-capital moat supports 40-50% gross margins and steady EBITDA conversion, producing predictable cash flows without heavy expansion capex.
- 600+ dietitians (2025)
- ~12% turnover (2025)
- 8 European markets active (2025)
- €45-55m ARR (2025 est.)
- 40-50% gross margin (2025)
- Low expansion capex; high cash conversion
Oviva: £39m FY25, €50m ARR, 62-72% margins, low CAC, €18/mo unit cost, £45m debt
Oviva's Cash Cows: stable NHS/Swiss contracts, FY2025 revenues £39.2m (UK £21m NDPP + £18.2m T2D) and €14.5m (DE); ARR €50m est.; gross margins 62-72%; CAC
Metric
FY2025
UK NDPP rev
£21m
UK T2D rev
£18.2m
DE T2D rev
€14.5m
ARR
€50m
Gross margin
62-72%
CAC/unit
Dietitians
600+
Debt
£45m
What You're Viewing Is Included
Oviva BCG Matrix
The file you're previewing is the exact Oviva BCG Matrix report you'll receive after purchase-no watermarks, no draft content-just a polished, analysis-ready document formatted for immediate use.
